Arcutis Biotherapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting net product revenue of $143.9 million for the third quarter.

Key Highlights

  • Net product revenue of $143,919 thousand for the three months ended September 30, 2026, up from $99,219 thousand in the same period of 2025, according to the filing.
  • Nine-month net product revenue of $379,178 thousand for the period ended September 30, 2026, compared to $244,569 thousand for the same period in 2025.
  • Total assets of $524,426 thousand as of September 30, 2026, versus $432,973 thousand at December 31, 2025.
  • Accumulated deficit narrowed to $1,125,569 thousand at September 30, 2026, compared to $1,138,084 thousand at December 31, 2025.
  • 126,018 thousand shares of common stock issued and outstanding as of September 30, 2026, with 126,455,033 shares outstanding as of October 30, 2026.
  • Marketable securities of $226,087 thousand at September 30, 2026, up from $178,075 thousand at December 31, 2025.
  • Total operating expenses of $134,483 thousand for Q3 2026, compared to $90,693 thousand in Q3 2025.

Arcutis Reports Accelerating Product Revenue and Narrowing Deficit in Q3 2026

According to the filing, Arcutis Biotherapeutics (NASDAQ:ARQT) reported net product revenue of $143,919 thousand for the three months ended September 30, 2026, a significant increase from $99,219 thousand in the comparable prior-year quarter. For the nine months ended September 30, 2026, net product revenue totaled $379,178 thousand, compared to $244,569 thousand for the same period in 2025. The company disclosed no other revenue in the 2026 periods, whereas the prior-year nine-month period included $2,000 thousand in other revenue.

The filing disclosed total operating expenses of $134,483 thousand for Q3 2026, broken down as cost of sales of $12,460 thousand, research and development expenses of $22,422 thousand, and selling, general and administrative expenses of $99,601 thousand. For the nine months ended September 30, 2026, the company reported total operating expenses of $362,402 thousand, including cost of sales of $33,183 thousand, research and development of $73,404 thousand, and selling, general and administrative costs of $255,815 thousand.

On the balance sheet, the registrant reported total assets of $524,426 thousand as of September 30, 2026, up from $432,973 thousand at December 31, 2025. The company's accumulated deficit stood at $1,125,569 thousand at September 30, 2026, a reduction from $1,138,084 thousand at year-end 2025. Total stockholders' equity increased to $243,966 thousand from $189,479 thousand over the same period. Cash and cash equivalents were $33,373 thousand, while inventory grew to $45,669 thousand from $22,634 thousand at December 31, 2025. Long-term debt, net, was reported at $102,448 thousand. The filing noted that forward-looking statements are subject to the company's cautionary language as described in Part II, Item 1A.

What Was Disclosed

Arcutis Biotherapeutics filed its quarterly report for the period ended September 30, 2026, disclosing Q3 net product revenue of $143,919 thousand, total assets of $524,426 thousand, a reduced accumulated deficit of $1,125,569 thousand, and 126,455,033 shares outstanding as of October 30, 2026.